Ipatasertib is an orally bioavailable inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic activity.

Capivasertib is an orally available inhibitor of the serine/threonine protein kinase AKT (protein kinase B) with potential antineoplastic activity.

AT7867 is a potent ATP-competitive inhibitor of Akt1/2/3 and p70S6K/PKA.

TIC10 inactivates Akt and ERK to induce TRAIL through Foxo3a, possesses superior drug properties: delivery across the blood-brain barrier, superior stability and improved pharmacokinetics.

CHIR-99021 HCl is a GSK-3α/β inhibitor.

SB216763 is a potent and selective GSK-3 inhibitor.

TWS119 is a GSK-3β inhibitor.

Tideglusib is an irreversible, non ATP-competitive GSK-3β inhibitor.